Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.4.1 (phosphodiesterase)
18,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In an attempt to identify the nature of guanine nucleotide binding protein(s) (G-protein) involved in the acetylcholine (ACh)-induced (muscarinic) response of pig coronary-artery smooth muscle, we studied the effect of ADP-ribosylation of specific membrane protein(s) catalysed by islet-activating protein (IAP; pertussis toxin). The ACh-stimulated and guanine nucleotide-dependent activities of phosphatidylinositol 4,5-bisphosphate (PIP2) phosphodiesterase (PDE), assessed by the production of inositol 1,4,5-trisphosphate (IP3) from exogenously applied PIP2, were not modified, in either IAP-treated or non-treated cell homogenates used as the enzyme source. In intact tissues, pretreatment with up to 100 ng of IAP/ml inhibited neither the ACh-induced decrease in the amount of inositol phospholipids nor the increase in the amounts of phosphatidic acid and of inositol phosphates. IAP treatment increased the amount of cyclic AMP accumulated by isoprenaline. These observations suggest that G-protein which couples the muscarinic receptor to PIP2-PDE is insensitive to IAP. Such being the case, the nature of this protein(s) probably differs from that required for the regulation of adenylate cyclase activities (Ni or Gi).
...
PMID:Guanine nucleotide binding protein involved in muscarinic responses in the pig coronary artery is insensitive to islet-activating protein. 303 Feb 65

It has been proposed elsewhere [Meeker, R.B. & Harden, T. K. (1982) Mol. Pharmacol. 22, 310-319] that muscarinic cholinergic receptor-mediated attenuation of cAMP accumulation occurs through activation of phosphodiesterase in 1321N1 human astrocytoma cells. Pertussis toxin, which ADP-ribosylates the guanine nucleotide regulatory protein involved in receptor-mediated inhibition of adenylate cyclase (Ni), has been utilized to further differentiate between the mechanism of cholinergic regulation of cAMP metabolism in 1321N1 cells and the mechanism involving inhibition of adenylate cyclase in other tissues. Muscarinic receptor-mediated regulation of cAMP accumulation in NG108-15 neuroblastoma-glioma cells occurs through inhibition of adenylate cyclase. Pretreatment of these cells with pertussis toxin completely blocked the capacity of carbachol to attenuate cAMP accumulation. In contrast, concentrations of pertussis toxin two to three orders of magnitude higher than those effective in NG108-15 cells had no effect on muscarinic receptor-mediated attentuation of cAMP accumulation in 1321N1 cells. In addition, no effect of pertussis toxin was observed either on the control rate or the carbachol-stimulated rate of cAMP degradation measured directly in intact 1321N1 cells. A 41,000 Mr protein previously proposed to be the alpha subunit of Ni was labeled during incubation of a plasma membrane fraction from 1321N1 cells with [32P]NAD and pertussis toxin. Pertussis toxin is apparently active in 1321N1 cells, since this protein substrate was not labeled in plasma membrane preparations from cells previously incubated with toxin. Functional activity of Ni was demonstrated by the observation that guanosine 5'-[gamma-thio]triphosphate- and GTP-mediated inhibition of forskolin-stimulated adenylate cyclase activity occurred in cell-free preparations from 1321N1 cells. The inhibitory activity of these guanine nucleotides was lost in membrane preparations from pertussis toxin-treated cells. The data suggest that adenylate cyclase is not involved in cholinergic action in 1321N1 cells and, furthermore, Ni is not involved in muscarinic receptor-mediated activation of phosphodiesterase in these cells. Thus, pertussis toxin can be used to differentiate between two mechanisms of cholinergic regulation of cAMP metabolism.
...
PMID:Pertussis toxin differentiates between two mechanisms of attenuation of cyclic AMP accumulation by muscarinic cholinergic receptors. 609 Nov 3

The attenuation of cyclic AMP accumulation occurs by different mechanisms in 1321N1 astrocytoma cells and NG108-15 neuroblastoma X glioma cells. In 1321N1 cells, cholinergic agonists reduce cyclic AMP accumulation through a Ca2+-dependent activation of phosphodiesterase; in NG108-15 cells, muscarinic receptor-mediated effects on cyclic AMP metabolism occur through inhibition of adenylate cyclase. The goal of the current study was to determine whether different pharmacological specificities were expressed by the muscarinic receptor populations of these two cell lines. The affinity of muscarinic receptors for [3H]quinuclidinyl benzilate (6 pM), [3H]N-methylscopolamine (50 pM), and atropine (80 pM) was similar in membrane preparations from each cell line. The affinity of the antagonist, pirenzepine, which has been proposed to be a selective ligand for a muscarinic receptor subtype, was 3-fold higher in competition binding assays carried out with membranes of 1321N1 cells, than with NG108-15 cells. The Hill coefficients of pirenzepine competition curves were not significantly different from unity in both cell lines. This selectivity of pirenzepine was also apparent in studies of the competitive inhibition of carbachol-induced attenuation of cyclic AMP accumulation in intact cells. Differences in the relative affinities of agonists were observed in competition binding analyses carried out with membranes in the presence of GTP and absence of Mg2+. The Ki values of bethanechol and carbachol were 5- and 12-fold lower for receptors of NG108-15 cells than those of 1321N1 cells and the Ki of methacholine was 3.5-fold lower for 1321N1 cells than for NG108-15 cells. The affinities of oxotremorine and arecoline were similar between the two cell lines. These differences in agonist affinities between the two cell lines were much smaller in analyses of muscarinic receptor-mediated effects on cyclic AMP metabolism in intact cells. Taken together, these data suggest that muscarinic receptors of differing pharmacological specificities regulate cyclic AMP metabolism by different mechanisms in 1321N1 and NG108-15 cells.
...
PMID:Muscarinic cholinergic receptors of two cell lines that regulate cyclic AMP metabolism by different molecular mechanisms. 609 92

To study the regulation of pepsinogen secretion by chief cells, we have developed techniques for the isolation, enrichment, and short-term culture of chief cells from canine stomach. The fundic mucosa was enzyme dispersed and chief cells were enriched to a content of about 70% using an elutriator rotor. After 36 h in culture confluent monolayers formed that were highly enriched in chief cells. Carbachol induced a time-dependent release of pepsinogen into the medium, with about a threefold increase in pepsinogen secretion over controls found after 60 min of incubation. Carbachol stimulation of pepsinogen secretion was dose dependent, with 5 microM producing 50% of the maximal response found at a carbachol concentration of 100 microM. Atropine (100 microM) produced a rightward shift of the dose-response curve, indicating the presence of a muscarinic receptor. Dibutyryl cAMP, 8-bromo-cAMP, and forskolin also markedly stimulated pepsinogen secretion. Secretin and vasoactive intestinal peptide (VIP) stimulated pepsinogen secretion, but the response were of smaller magnitude than found with carbachol or the cAMP analogues. The phosphodiesterase inhibitor isobutylmethylxanthine also caused a small stimulation of pepsinogen secretion but did not enhance the response to secretin or VIP. These findings indicate that epithelial monolayers can spontaneously form from isolated canine chief cells and retain functional differentiation evident by a response to stimulation. Canine chief cells in culture possess muscarinic and secretin receptors and respond to cAMP.
...
PMID:Regulation of pepsinogen release from canine chief cells in primary monolayer culture. 619 27

The cholinergic agonist, carbachol, produces a small increase in cyclic AMP concentration in the isolated rat retina, and markedly potentiates dopamine-stimulated cyclic AMP formation. This effect of carbachol is mediated through a muscarinic receptor, is calcium-independent, and is not due to inhibition of phosphodiesterase activity. Activation of muscarinic receptors may potentiate dopaminergic responses in the retina by enhancing coupling of the dopamine receptor to adenylate cyclase.
...
PMID:Muscarinic-dopaminergic synergism on retinal cyclic AMP formation. 626 79

Activation of muscarinic cholinergic receptors on 1321N1 human astrocytoma cells results in a 40-70% inhibition of isoproterenol- or prostaglandin E1 (PGE1)-stimulated accumulation of cyclic AMP. Previous investigations have demonstrated that this effect is due to a Ca2+-dependent activation of phosphodiesterase in the presence of muscarinic receptor agonists. However, during prolonged exposure of 1321N1 cells to a cholinergic agonist, a series of adaptive changes occurs which culminates in a complete loss of the muscarinic receptor-mediated inhibition of cyclic AMP accumulation. These alterations include: (a) A 50-100% increase in the capacity of isoproterenol and PGE1 to stimulate cyclic AMP accumulation. This phenomenon was rapid in onset, reached a maximum in 15-20 min, and disappeared over the next 2 hr even in the continued presence of carbachol. (b) A loss of the effects of muscarinic receptor stimulation on cyclic AMP accumulation. This phenomenon was apparent within 15 min after addition of carbachol, and complete desensitization was observed after 75 min. The loss of muscarinic receptor-mediated effects on cyclic AMP levels was due to a loss of the Ca2+-dependent stimulation of phosphodiesterase activity by muscarinic receptor agonists. (c) A loss of muscarinic receptors as assessed by [3H]quinuclidinyl benzilate binding. This effect was apparent after 90 min in the presence of carbachol. More than 80% of the receptors were lost after 24 hr, with no change occurring in the KD of [3H]quinuclidinyl benzilate. The concentration-effect curve for carbachol-induced changes in agonist responsiveness of the cyclic AMP system was similar to that for carbachol-induced reductions in cyclic AMP levels. Coincubation of carbachol with a saturating concentration of atropine prevented these adaptive changes from occurring. Although incubation of cells in Ca2+-free buffer or in the presence of 20 mM Co2+ prevented the inhibitory effects of muscarinic receptor stimulation on cyclic AMP accumulation, carbachol preincubations under these conditions still produced the adaptive changes in agonist responsiveness. The divalent cation ionophore, A23187, mimics the effects of muscarinic receptor stimulation on cyclic AMP levels by activating phosphodiesterase. Following complete carbachol-induced loss of responsiveness to muscarinic receptor agonists, A23187 was still capable of inhibiting cyclic AMP accumulation.
...
PMID:Muscarinic cholinergic receptor-mediated control of cyclic AMP metabolism. Agonist-induced changes in nucleotide synthesis and degradation. 630 Jun 48

Intracerebroventricular (i.c.v.) administration of dibutyryl cyclic AMP (Db-cAMP)- and dibutyryl cyclic GMP (Db-cGMP)-induced hyperthermia in rabbits. Central administration of 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711), a selective inhibitor of cAMP phosphodiesterase, only accentuated the hyperthermia due to Db-cAMP whereas a selective inhibitor of cGMP phosphodiesterase, 2-O-proproxyphenyl-8-azapurin-6-one (M and B 22948), only potentiated the hyperthermia caused by Db-cGMP. The hyperthermia due to Db-cAMP and Db-cGMP was not mediated through prostaglandins (PG). In contrast, central administration of an alpha-adrenergic receptor antagonist, phenoxybenzamine, or a beta-adrenergic receptor antagonist, sotalol, only attenuated the hyperthermic response to Db-cAMP while a cholinergic muscarinic receptor antagonist, atropine, specifically antagonized Db-cGMP-induced hyperthermia. I.c.v. administration of a protein synthesis inhibitor, anisomycin, did inhibit the hyperthermia due to Db-cAMP and Db-cGMP. Opiate antagonist, naloxone, did not antagonize Db-cAMP- and Db-cGMP-induced hyperthermia. These results suggest that a protein mediator is implicated in the induction of hyperthermia by Db-cAMP and Db-cGMP and that cAMP and cGMP may be involved through alpha/beta-adrenergic and cholinergic muscarinic receptors respectively in the central regulation of heat production/conservation in rabbits.
...
PMID:Central effects of dibutyryl cyclic AMP and GMP on the temperature in conscious rabbits. 631 45

We studied the role of cyclic guanosine monophosphate (cGMP) as a mediator of the reduction of L-type calcium current (ICa) induced by muscarinic receptor stimulation and by nitric oxide in isolated guinea-pig ventricular cells using the whole-cell patch-clamp technique. Our results show that when the level of cyclic adenosine monophosphate was increased by the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX), stimulation of a pertussis-toxin (PTX)-sensitive muscarinic receptor by carbachol (1 microM) reduced the calcium current increase from 80.6 +/- 23.5% to 19.8 +/- 9.6% over the control and this effect was prevented by methylene blue (10 microM), an inhibitor of the soluble guanylate cyclase. Pipette solution containing 10 microM cGMP reduced the enhancement of ICa by IBMX from 121.9 +/- 11.6% to 14.2 +/- 5.4% above the control. Sodium nitroprusside (10 microM), a spontaneous donor of nitric oxide, and consequently a stimulator of soluble guanylate cyclase, also reduced IBMX-stimulated ICa from 115.2 +/- 13.2% to 32.2 +/- 6.9% above control and the sodium nitroprusside effect was also suppressed by methylene blue. The latter two reagents were ineffective on basal ICa.
...
PMID:Guanylate-cyclase-mediated inhibition of cardiac ICa by carbachol and sodium nitroprusside. 751 32

At least 30 G protein-linked receptors stimulate phosphatidylinositol 4,5-bisphosphate phosphodiesterase (phospholipase C beta, PLC beta) through G protein subunits to release intracellular calcium from the endoplasmic reticulum (Clapham, D. E. (1995) Cell 80, 259-268). Although both G alpha and G beta gamma G protein subunits have been shown to activate purified PLC beta in vitro, G alpha q has been presumed to mediate the pertussis toxin-insensitive response in vivo. In this study, we show that G beta gamma plays a dominant role in muscarinic-mediated activation of PLC beta by employing the Xenopus oocyte expression system. Antisense nucleotides and antibodies to G alpha q/11 blocked the m3-mediated signal transduction by inhibiting interaction of the muscarinic receptor with the G protein. Agents that specifically bound free G beta gamma subunits (G alpha-GDP and a beta-adrenergic receptor kinase fragment) inhibited acetylcholine-induced signal transduction to PLC beta, and injection of G beta gamma subunits into oocytes directly induced release of intracellular Ca2+. We conclude that receptor coupling specificity of the G alpha q/G beta gamma heterotrimer is determined by G alpha q; G beta gamma is the predominant signaling molecule activating oocyte PLC beta.
...
PMID:The G protein beta gamma subunit transduces the muscarinic receptor signal for Ca2+ release in Xenopus oocytes. 853 Apr 11

The ability of agents that increase or mimic cAMP to affect muscarinic receptor mediated phosphoinositide hydrolysis was investigated in the rat parotid gland. Forskolin (10 microM) and isoproterenol (10 microM) elevated cAMP in the parotid gland by 2-fold and 7-fold, respectively, and these agents also inhibited oxotremorine-M (3 microM) mediated phosphoinositide hydrolysis by 14% and 26%, respectively. Forskolin (1, 4.3, 18, and 75 microM) increased cAMP accumulation and inhibited PIP2 hydrolysis in a concentration-dependent manner. Forskolin (75 micrometers) shifted the concentration-response curve for the full agonist oxotremorine-M rightward by 4.2-fold. Pre-treatment with the phosphodiesterase inhibitor isobutylmethylxanthine (1 mM) reduced the maximum effect of oxotremorine-M by 31%. The inhibitory effect of isoproterenol and forskolin on muscarinic receptor-mediated phosphoinositide hydrolysis was unaffected by the removal of extracellular Ca2+. Moreover, isoproterenol and forskolin dampened sodium fluoride and oxotremorine-M mediated phosphoinositide hydrolysis to the same extent suggesting that the inhibitory effect of cAMP is downstream from the muscarinic receptor.
...
PMID:Inhibition of muscarinic stimulated phosphoinositide hydrolysis in the rat parotid gland by cAMP. 860 23


<< Previous 1 2 3 4 5 6 7 Next >>

---